Management of acute urinary retention in men with benign prostatic hyperplasia: Literature review and guidelines from the French Urological Association Male LUTS Panel (CTMH)
Abstract
INTRODUCTION
Acute urinary retention (AUR) is a common urological emergency, particularly in elderly men, often associated with benign prostatic hyperplasia (BPH). It requires prompt intervention to relieve symptoms and prevent complications. The French Urological Association Male LUTS Panel (CTMH) aimed to develop evidence-based guidelines for managing BPH-related AUR in men.
METHODS
A systematic PubMed literature review was conducted, evaluating studies by level of evidence and methodological quality. Guidelines were developed through CTMH member consensus.
RESULTS
Drainage method selection (urethral or suprapubic catheter) should consider patient-specific contraindications. Suprapubic catheterization may offer superior patient comfort and reduced colonization rates. Clean intermittent self-catheterization represents a viable alternative with improved quality of life. Alpha-blockers (alfuzosin 10mg, tamsulosin 0.4mg, silodosin 8mg) administered for 2-3days significantly improve trial without catheter success rates, with no agent demonstrating superiority. Short catheterization duration (60, known BPH). Evidence remains insufficient to recommend immediate surgery without trial without catheter or to establish optimal surgical technique.
CONCLUSION
These CTMH guidelines provide evidence-based recommendations for AUR management, emphasizing alpha-blocker therapy before trial without catheter and considering patient-specific factors when selecting drainage methods. Further…
Read the paper
Related studies
- Erectile dysfunction
- Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit
- Alpha1-adrenoceptor subtypes and lower urinary tract symptoms
- Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets
- Chronic bladder ischemia and oxidative stress: New pharmacotherapeutic targets for lower urinary tract symptoms
- The role of prostate inflammation and fibrosis in lower urinary tract symptoms
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.